MYPHALOR Trademark

Trademark Overview


On Tuesday, December 18, 2018, a trademark application was filed for MYPHALOR with the United States Patent and Trademark Office. The USPTO has given the MYPHALOR trademark a serial number of 88232851. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 18, 2022. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The MYPHALOR trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of ...
myphalor

General Information


Serial Number88232851
Word MarkMYPHALOR
Filing DateTuesday, December 18, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 18, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 16, 2019

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely, fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, January 9, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, July 18, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 18, 2022ABANDONMENT - NO USE STATEMENT FILED
Wednesday, December 8, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, December 7, 2021SOU EXTENSION 5 GRANTED
Tuesday, November 30, 2021SOU EXTENSION 5 FILED
Tuesday, December 7, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 30, 2021TEAS EXTENSION RECEIVED
Saturday, June 12, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 10, 2021SOU EXTENSION 4 GRANTED
Thursday, June 10, 2021SOU EXTENSION 4 FILED
Thursday, June 10, 2021TEAS EXTENSION RECEIVED
Friday, December 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 9, 2020SOU EXTENSION 3 GRANTED
Wednesday, December 9, 2020SOU EXTENSION 3 FILED
Wednesday, December 9, 2020TEAS EXTENSION RECEIVED
Wednesday, June 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 8, 2020SOU EXTENSION 2 GRANTED
Monday, June 8, 2020SOU EXTENSION 2 FILED
Monday, June 8, 2020TEAS EXTENSION RECEIVED
Wednesday, December 4, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 6, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 4, 2019SOU EXTENSION 1 GRANTED
Wednesday, December 4, 2019SOU EXTENSION 1 FILED
Wednesday, December 4, 2019TEAS EXTENSION RECEIVED
Tuesday, June 11, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 16, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 16, 2019PUBLISHED FOR OPPOSITION
Wednesday, March 27, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, March 8, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, March 8, 2019ASSIGNED TO EXAMINER
Wednesday, January 9, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, December 21, 2018NEW APPLICATION ENTERED IN TRAM